Celyad Announces Commercial License Agreement for C-Cure® in Greater China
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
UBS Reiterates Buy on Celyad SA (CYAD) Following Announced Collaboration with Medisun
September 1, 2015 10:08 AM EDTUBS reiterated a Buy rating and $79.00 price target on Celyad SA (NASDAQ: CYAD) following the announced strategic collaboration and distribution agreement with Medisun. Analyst Andrew Peters believes that the agreement opens the door to a potentially large and underserved market opportunity.
Peters... More
Celyad SA (CYAD), Medisun Enter Collaboration in China
August 31, 2015 6:26 AM EDTCelyad SA (NASDAQ: CYAD) announced that it has entered into a new collaboration and distribution agreement with its Hong-Kong based partner, Medisun International Limited ("Medisun"). This license agreement confirms Celyad's intention to expand the global footprint of its lead cardiac disease cell therapy candidate for the treatment of ischemic heart failure, C-Cure®.
Under the terms of the new license agreement, Celyad will conduct all clinical development and undertake any regulatory steps necessary for market approval in China, Hong-Kong, Taiwan and Macau (collectively "Greater China"). With a minimum of 20 million, these activities will be funded... More
